Mari Edlin
Mari Edlin is a frequent contributor to Managed Healthcare Executive. She is based in Sonoma, California.
Scammers, Fraudsters Capitalize on Opioid Addiction Treatment
A lack of national standards and less than optimal oversight of many inpatient, opioid addiction rehabilitation programs is raising questions about the level of services, personnel, and quality of care many patients are receiving.
The top three pharmacy challenges of 2018
The top three pharmacy challenges of 2018
Find out what challenges top the list, and what analysts say can be done about them.
Four therapeutic areas to watch in 2018
Four therapeutic areas to watch in 2018
Prepare for major pipeline developments in diabetes, autoimmune disorders, oncology, and COPD.
New RA drugs and pipeline developments to watch
Treating RA is a work in progress. Here’s what you need to know.
Controversy heats up over pharmacy benefit manager DIR fees
PBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.
Top solutions to lower drug prices
PBMs partnering with pharmacies and drug makers may have a solution to nonadherence due to high pharma costs.
Controversy surrounds Exondys 51 approval: What to know
New medicine for Duchenne muscular dystrophy raises questions. Here’s whose covering it and why.
Four health systems develop opioid mitigation programs
Alternatives to opioids programs emerge as viable tools to mitigate the crisis.
Value-based drug contracting shifts risk to manufacturers
Value-based drug contracting between manufacturers and payers is picking up steam—appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.
Autoimmune drug pipeline: What health execs should watch
New drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.


View Results